Inmunoterapia en 1L del CPCNP: monoterapia y/o tratamiento combinado - page 39

3. Duración del tratamiento
Robert C , et al. ASCO 2016
Herbst R, et al. WCLC 2016
• ORR: 89%
• DCR ≥6 months: 100%
• Median time to response: 2 months
• 72% of responses were ongoing
Patients (n=47) Completing 24 m Pembro
KeyNote 010